Introduction {#Sec1}
============

Extracorporeal membrane oxygenation (ECMO) is a method for supporting patients with severe adult respiratory distress syndrome (ARDS) refractory to mechanical ventilation \[[@CR1]--[@CR3]\]. ECMO has been used in neonates and children with satisfactory outcomes \[[@CR4], [@CR5]\]. More recently, technical advances have enabled its safer application in adults \[[@CR3], [@CR6]\]. Among such adults, occasional patients have been supported with ECMO while pregnant or in the postpartum period. Such treatments have led to individual case reports only \[[@CR7]--[@CR15]\]. This lack of information makes it difficult to assess the safety and efficacy of this procedure in pregnant women and to estimate how it might affect maternal and/or infant outcome.

In the winter of 2009, 760 patients were admitted to intensive care units (ICUs) in Australia and New Zealand with the pandemic swine-origin (H1N1) influenza \[[@CR16]\]. ECMO was used in 68 adult patients who had either H1N1 influenza or strongly suspected H1N1 influenza \[[@CR17]\]. Of these, 10 were pregnant or postpartum, which were described as part of the published cohort \[[@CR17]\]. Two patients presented immediately subsequent and were added to aggregate to a series of 12, thereby providing the largest source of information to date on the safety and efficacy of ECMO during pregnancy. Accordingly, we now report on the various technical aspects and challenges of ECMO therapy in this cohort of pregnant and postpartum women with severe respiratory failure and describe maternal and infant outcomes.

Methods {#Sec2}
=======

Study design {#Sec3}
------------

Data collection was approved by the relevant human research ethics committees. We collected information on all pregnant and postpartum women (within 28 days of delivery) treated with ECMO for confirmed or strongly suspected 2009 H1N1 influenza-associated respiratory failure during the 2009 winter period (June 1st through September 30th) in the ICUs that provided ECMO support in Australia and New Zealand.

Women who were postpartum at the time of ECMO commencement, but pregnant at the onset of influenza were included as they still had the anatomical, physiological and immunological alterations associated with pregnancy.

Data collection {#Sec4}
---------------

Please see the electronic supplementary material (ESM) for details of data collection and statistical analysis.

Results {#Sec5}
=======

Patient characteristics at the time of ECMO commencement {#Sec6}
--------------------------------------------------------

Of the 12 patients treated with ECMO, 7 (58%) were pregnant and 5 (42%) were postpartum. The median (IQR) age was 29 (26--33) years. The associated comorbidities are summarized in Table [1](#Tab1){ref-type="table"}. A diagnosis of H1N1 infection was confirmed in 10 (83%) patients, 1 had positive serology for influenza A and 1 had clinical features highly suggestive of influenza during a pandemic. Details regarding the severity of ARDS and the ECMO technical characteristics are described in the ESM and Table [1](#Tab1){ref-type="table"}.Table 1Patient characteristics prior to initiation of ECMO therapyPatient numberGestation/postpartumAge (years)ComorbiditiesDuration of MV prior to ECMO (days)SpO~2~ (%)PaO~2~/FiO~2~ ratioPaCO~2~ (mmHg)Max PEEP (cm)Rescue therapiesOther organ support126 weeks34Obesity\<155276820RM213 weeks22Asthma1088659914PGI~2~RM321 weeks23AsthmaObesity184515013iNOVasoactiveRM423 weeks33Obesity182316220PGI~2~VasoactiveRM520 weeks421693715015ProneiNO, RM626 weeks39Asthma\<1N/A425420iNOCRRT vasoactiveRM730 weeks2910907210215ProneVasoactive8Postpartum27Obesity881536020ProneCRRT vasoactiveiNO, RM9Postpartum29292493818ProneVasoactiveiNO, RM10Postpartum23Diabetes983503015RM11Postpartum27Obesity591336027RM12Postpartum32ObesityCorrected TOF192568924iNOCRRT vasoactiveRMGestation was documented at time of ICU admission*BMI* body mass index, *iNO* inhaled nitric oxide, *RM* recruitment manouevres, *MV* mechanical ventilation, *PGI*~*2*~ nebulised prostacyclin, *TOF* tetralogy of Fallot, *PaCO*~*2*~ partial pressure of carbon dioxide in arterial blood, *PEEP* positive end-expiratory pressure, *CRRT* continuous renal replacement therapy, *vasoactive* vasoactive drug infusions,*N/A* not available

Details of ICU support {#Sec7}
----------------------

The median (IQR) duration of mechanical ventilation was 25 (18--32) days. Seven (58%) patients required a tracheostomy to facilitate weaning from ventilation. All 12 patients received packed red blood cell transfusion during ECMO therapy. The median (IQR) volume of blood transfused per patient during ECMO therapy was 3,499 (1,451--4,874) ml. Five patients required platelet transfusions, 3 of who also required fresh frozen plasma. All patients received vasoactive drug infusions at some time during ECMO therapy.

The median (IQR) duration of ECMO support was 14 (9--19) days. The length of ICU stay and hospital stay is reported in Table [3](#Tab3){ref-type="table"}.

Technical details {#Sec8}
-----------------

Ten (83%) patients initially received VV ECMO and 2 (17%) received VA ECMO (Table [2](#Tab2){ref-type="table"}). VA ECMO was the initial choice in the two patients due to the finding of moderate or severe left ventricular dysfunction on echocardiography. All patients had vascular cannulae inserted peripherally by a percutaneous Seldinger technique. Six (50%) patients received an additional venous drainage line (2 drainage lines and 1 return line) as blood flow rates through the circuit were deemed inadequate for effective therapy (Table [2](#Tab2){ref-type="table"}).Table 2Technical details of ECMO supportPatient numberECMO configurationNo. of sitesSite and size of access cannula/eSite and size of return cannulaFlow at 4 h (L/min)Flow at 24 h (L/min)1V-V2 drainage1 returnRIJ 19, LF 23RF 237.37.22V-V1 drainage1 returnRF 23LF 213.13.13V-V1 drainage1 returnRF 21RIJ 175.144V-V1 drainage1 returnRF 21LF 235.04.15V-V1 drainage1 returnRF 23RIJ 195.46.46V-V1 drainage1 returnRF 22LF 18N/AN/A7V-V2 drainage1 returnLF 25, RF 23RIJ 193.948V-A to V-V2 drainage1 returnLF 25, RIJ 21RF 199.16.59V-V1 drainage1 returnRF 21RIJ 1832.910V-V2 drainage1 returnRF 23 RIJ 17LF 213.43.911V-V2 drainage1 returnRF 23, RIJ 17LF 214.95.212V-A to V-V2 drainage1 returnRF 25, RIJ 17LF 196.16Cannula size in French*V-V* venovenous, *V-A* veno-arterial, *RF* right femoral, *LF* left femoral, *RIJ* right internal jugular, *N/A* not available

All circuits used a Quadrox D oxygenator (Maquet, Rastatt, Germany) and in 11 (92%) patients, a Jostra pump head (Maquet, Rastatt, Germany). All patients received therapeutic anticoagulation (Table [2](#Tab2){ref-type="table"}). In 10 (83%) patients, a single circuit was utilized for the duration of the entire treatment, whereas two patients required a circuit change due to progressive failure of the initial circuit. Blood flow through the ECMO circuit at 4 and 24 h is reported in Table [2](#Tab2){ref-type="table"}.

Outcomes {#Sec9}
--------

Eight (66%) patients were successfully weaned from ECMO, all of who survived to hospital discharge (Table [3](#Tab3){ref-type="table"}). Of these, 7 (88%) were discharged home and 1 patient was discharged to a rehabilitation facility. All eight patients were ambulant at discharge with a median room air oxygen saturation of 95% (95--97). Six of the eight survivors were assessed for quality of life between 12 and 18 months after hospital discharge using the Short Form 36 (SF36v2^®^) tool. Their summary scores in both the physical health and mental health components were found to be similar to the Australian norms for an age- and sex-matched population. Two non-survivors were pregnant and two were postpartum. Of the four non-survivors, two died of bleeding (other than intracranial; one pulmonary and one from multiple sites), one died from intracranial haemorrhage and one of overwhelming fungal infection. Details of bleeding complications are included in Table [4](#Tab4){ref-type="table"}.Table 3Maternal and infant outcomesPatient no.Pregnant/postpartumECMO duration (days)MV duration (days)ICU LOS (days)Hospital LOS (days)Maternal outcomeInfant outcome1Pregnant18344043SurvivedSurvived2Pregnant2172227SurvivedSurvived3Pregnant11222842SurvivedSurvived4Pregnant5161726SurvivedStillborn5Pregnant207883112SurvivedStillborn6Pregnant\<1447DiedSurvived7Pregnant20303333DiedSurvived8Postpartum17252528DiedSurvived9Postpartum10182024SurvivedSurvived10Postpartum27363543DiedSurvived11Postpartum15323853SurvivedSurvived12Postpartum12314275SurvivedSurvived*LOS* length of stay, *MV* mechanical ventilation Table 4Anticoagulation and bleeding complicationsPatient numberAnticoagulationAPTT mean^a^ (SD)Bleeding siteMaternal outcome1Heparin76 (23)NilSurvived2Heparin61 (22)NilSurvived3Heparin112 (37)NilSurvived4Heparin152 (66)UterineSurvived5Heparin152 (59)PulmonarySurvived6HeparinN/AMultipleDied7Heparin70 (12)IntracranialDied8Heparin69 (12)ECMO cannulaDied9Heparin95 (66)NilSurvived10Heparin54 (19)PulmonaryDied11Heparin72 (14)ECMO cannulaSurvived12Heparin76 (8)FasciotomySurvived*APPT* activated partial thromboplastin time,*SD* standard deviation, *N/A* not available^a^Mean of highest daily APTT value (in seconds) achieved during ECMO therapy

Table [5](#Tab5){ref-type="table"} shows comparative outcomes between this cohort of patients and the non-pregnant cohort of 18 women of childbearing age (15--45 years) who received ECMO support during the same time period.Table 5Comparison of pregnant/postpartum patient cohort with other women of childbearing age (15--45 years) who received ECMO during the same time periodVariablePregnant/postpartum cohort (*N* = 12)Other women of childbearing age (*N* = 18)*p* ValueMedian age (IQR) (years)28 (24--32)34 (27--37)0.62Median duration of MV (IQR) (days)24 (17--32)22 (12--30)0.25Median duration on ECMO (IQR) (days)12 (6--17)10 (7--13)0.32Bleeding rate (%)67500.45Infection rate (%)58670.71Median ICU length of stay (IQR) (days)27 (21--37)21 (13--32)0.34Median hospital length of stay (IQR) (days)35 (24--43)25 (15--33)0.51Mortality (%)33281.0

Complications {#Sec10}
-------------

Eight (67%) patients suffered from bleeding complications (requiring transfusion) during ECMO support (Table [4](#Tab4){ref-type="table"}). Seven (58%) patients acquired one or more nosocomial infection. Of the infections encountered, one was bloodstream, four were respiratory, one was urinary tract, one was line-related and five were wound infections. One maternal death was attributed to infection.

Other significant complications noted were limb ischaemia in two cases in patients receiving VA ECMO (neither of which required amputation or embolectomy), and venous thromboembolism (1). No technical difficulties, such as accidental decannulation, disconnection, oxygenator failure, pump failure, haemolysis, air embolism or other circuit complications, were noted in this cohort of patients. There were no thrombotic complications.

Pregnancy and delivery details {#Sec11}
------------------------------

Three patients (25%) were primigravida. The median (IQR) gestational age at the time of ICU admission for the seven pregnant patients was 24 (21--27) weeks. None of the pregnant patients were in the first trimester of pregnancy. Of the five postpartum patients, all received ECMO therapy within a week of delivery. Three of the pregnancies (38%) were complicated by pre-eclampsia and one patient had a placenta praevia. There were no multiple pregnancies. Three patients (25%) had a preterm operative delivery due to the severity of the maternal illness. Of the 12 patients, 5 delivered spontaneously, 2 had vacuum-assisted delivery and 5 had caesarean sections (3 patients after ECMO therapy was completed, 1 just after ECMO was commenced due to extreme severity of maternal illness and 1 prior to the commencement of ECMO therapy).

Details of infants born to mothers following ECMO therapy (*n* = 7) {#Sec12}
-------------------------------------------------------------------

Five of the 7 (71%) infants delivered after commencement of ECMO were live births (Table [3](#Tab3){ref-type="table"}). Of the two stillborn infants, pregnancy was terminated due to the severity of maternal illness in one case and in the second, there was a spontaneous birth of a stillborn infant shortly after commencing ECMO treatment. The median gestational age at birth was 31 (25--36) weeks. The median birth weight was 1,570 (972--3,015) g. Two of the live-born infants had a low Apgar score (between 0 and 6) 5 min after birth. Four of 5 live-born infants were admitted to a special care unit for respiratory support. No congenital abnormalities were noted. All the live-born infants survived.

Discussion {#Sec13}
==========

Summary of principal findings {#Sec14}
-----------------------------

We studied the technical challenges, efficacy, complications and maternal and infant outcomes in a cohort of critically ill pregnant and postpartum patients with severe, hypoxic respiratory failure secondary to ARDS during the 2009 H1N1 pandemic who were treated with ECMO. We found that obesity (pre-pregnancy BMI \>30) was common and that, despite significant right ventricular dysfunction in four patients, only two were initially treated with VA ECMO and that adequate gas exchange was achieved in all cases. Circuit-related complications were rare; circuit change was needed in only two cases and there was no sudden circuit failure. On the other hand, bleeding was common and responsible for the transfusion of large volumes of packed red blood cells and significantly contributed to three of the four deaths. Eight (66%) patients survived and seven were ambulant and discharged with normal oxygen saturations. The survival of normal infants delivered while the mother was on ECMO was 71%.

Comparison with previous studies {#Sec15}
--------------------------------

Publications regarding the use of ECMO in pregnancy have, so far, only been single case reports. Of the five patients described with respiratory failure \[[@CR7]--[@CR11]\], four survived and of the five infants, three survived.

In the recent CESAR study \[[@CR6]\], a multi-centre randomized control trial comparing transfer to an ECMO centre for ECMO therapy to conventional mechanical ventilation alone in severe ARDS (but not pregnant patients), the survival rate for ECMO therapy was 63% overall. The Australian and New Zealand observational study \[[@CR17]\] of 68 adult patients treated with ECMO for severe respiratory failure during the winter of 2009 (of which some the patients reported in this study are a subset) reported an overall survival of 75% (95% CI 60--82%) \[[@CR12]\].

Significance of study findings {#Sec16}
------------------------------

Our study suggests that ECMO is an appropriate life supportive option in pregnant and postpartum patients with severe respiratory failure and extreme levels of hypoxia, and that when utilized in this setting, it can deliver acceptable maternal and infant outcomes. Such outcomes may be related to the very early use of ECMO, thereby limiting the duration of maternal hypoxia, hypercarbia and acidosis as well as limiting the duration of ventilator-associated lung injury. Bleeding was the most common complication of therapy and it was the major contributing factor in three deaths. This finding, the concurrent observations that no patient experienced thrombotic complications, that only two circuits required change and that none failed suddenly all indicate that these patients were likely relatively over-anticoagulated during ECMO. This may suggest the need for a conservative approach to anticoagulation during ECMO treatment in pregnant women.

Also, of clinical relevance is the observation that the presence of right ventricular dysfunction does not necessarily require VA ECMO support and that once mechanical ventilation is minimized and the right heart decompressed, the systemic circulation remains stable.

Study strengths and limitations {#Sec17}
-------------------------------

Our study is a retrospective case series, with the associated inherent shortcomings, including the lack of randomization of treatment to ECMO or standard care. Patient selection for ECMO and subsequent management of these challenging cases was determined by clinicians based on experience, limited current literature and local guidelines. However, equipment, policies and practices remained relatively homogenous owing to integrated intensive care services and training in our two countries. Our study does not report on the long-term pulmonary function tests of the mothers or the long-term neurological sequelae in the infants. Consequently, these results may not be generalisable to pregnant and postpartum patients who receive ECMO for other conditions. To our knowledge, however, this is the largest published series of pregnant and/or postpartum patients treated with ECMO. It includes the complete experience from our two countries during the 2009 pandemic. The propensity of the H1N1 virus to cause severe respiratory failure in young adults with an increased risk in pregnant and postpartum women \[[@CR18], [@CR19]\] enabled us to study a number of patients with similar lung pathology over a relatively short time span. The findings of our study have relevance to the treatment of future patients who may present with severe 2009 H1N1 ARDS in subsequent outbreaks.

Conclusions {#Sec18}
===========

ECMO support for severe respiratory failure is technically feasible in pregnant and postpartum patients---femoral vascular cannulation and prolonged circuit life are possible and adequate oxygenation is achievable despite the recognised augmented cardiac output. ECMO is effective, with outcomes comparable to those of non-pregnant patients, and acceptable infant outcomes. Although ECMO was relatively safe, with complication rates similar to other groups, major bleeding contributed to significant morbidity and mortality suggesting that a low anticoagulation or anticoagulation-free approach in future patients may be prudent.
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